Abstract
The pathogenesis of a number of chronic inflammatory processes can be attributed to prolonged neovascularization. This article reviews recent studies on the vasculature targeting strategies for the treatment of chronic inflammatory diseases. Targeting of the vasculature of inflamed organs could underlie a new pharmacological approach in the treatment of inflammatory diseases by taking advantage of formulations that deliver drugs to blood vessels specifically located at disease sites and to inflammatory cells.
Keywords: antiangiogenesis, chronic inflammatory diseases, vascular targeting
Current Drug Targets - Inflammation & Allergy
Title: Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Volume: 4 Issue: 1
Author(s): Girolamo Ranieri, Roberto Ria, Aldo M. Roccaro, Angelo Vacca and Domenico Ribatti
Affiliation:
Keywords: antiangiogenesis, chronic inflammatory diseases, vascular targeting
Abstract: The pathogenesis of a number of chronic inflammatory processes can be attributed to prolonged neovascularization. This article reviews recent studies on the vasculature targeting strategies for the treatment of chronic inflammatory diseases. Targeting of the vasculature of inflamed organs could underlie a new pharmacological approach in the treatment of inflammatory diseases by taking advantage of formulations that deliver drugs to blood vessels specifically located at disease sites and to inflammatory cells.
Export Options
About this article
Cite this article as:
Ranieri Girolamo, Ria Roberto, Roccaro M. Aldo, Vacca Angelo and Ribatti Domenico, Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases, Current Drug Targets - Inflammation & Allergy 2005; 4 (1) . https://dx.doi.org/10.2174/1568010053622966
DOI https://dx.doi.org/10.2174/1568010053622966 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Platelet-Rich Plasma Induces Mixed Osteogenic/Osteoclastogenic Phenotype in Osteosarcoma SaOS-2 Cells: Role of TGF-Beta
Current Pharmaceutical Biotechnology The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Hypericin - A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules
Current Drug Targets Occupational Risk Assessment of Engineered Nanomaterials: Limits, Challenges and Opportunities
Current Nanoscience Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology